Developments in cytotoxic chemotherapy: Advances in treatment utilising vinorelbine

Critical Reviews in Oncology/Hematology

Volumn 40, Issue 3, 2001, Pages 251-263

  Aapro, M S ^a   Harper, P ^b   Johnson, S A ^c   Vermorken, J B ^d  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b GUY S HOSPITAL   (United Kingdom)

^c TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Breast cancer; Combination chemotherapy; In vitro activity; Lung cancer; Vinorelbine

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTHRACYCLINONE DERIVATIVE; ANTIMETABOLITE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; MITOMYCIN C; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; VINCA ALKALOID; VINDESINE;

BREAST CANCER; CHEMOTHERAPY; CYTOTOXICITY; HUMAN; LUNG NON SMALL CELL CANCER; REVIEW;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DRUG SYNERGISM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; VINBLASTINE;

EID: 0035194287     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00167-6     Document Type: Review

References (137)

1. Phase I pharmacologic study of a new vinca alkaloid; Navelbine
2. Phase II study of Navelbine in advanced breast cancer
3. Mechanism of inhibition of cell proliferation by vinca alkaloids
4. Antiproliferative activity of vinorelbine (Navelbine) against six human melanoma cell lines
5. Efficacy of 5′-nor-anhydrovinblastine (vinorelbine), against freshly explanted clonogenic human tumour cells in vitro
6. Immunofluorescence study of the action of Navelbine; Vincristine and Vinblastine on mitotic and axonal microtubules
7. Effects of vinorelbine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro
8. Vinblastine induced phosphorylation of Bcl-2 and Bcl-XL is mediated by JNK and occurs in parallel with activation of the Raf-1/MEK/ERK cascade
9. Bcl 2 is the guardian of microtubule integrity
10. Vinorelbine induces apoptosis and caspase 3 (CPP 32) expression in leukaemia and lymphoma cells: a comparison with vincristine
11. In vitro synergy of paclitaxel (Taxol) and vinorelbine (Navelbine) against human melanoma cell lines
12. Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukaemia cells
13. Preclinical profile of docetaxel (Taxotere): efficacy as a single agent and in combination
14. Severe neurotoxicity from vinorelbine-paclitaxel combinations
15. Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines
16. Clinical pharmacokinetics of the antitumor drug Navelbine (5′-noranhydrovinblastine)
17. Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer
18. Phase I and pharmacologic study of intra-venous vinorelbine in patients with solid tumors
19. A phase II study of Navelbine (vinorelbine) in the treatment of non-small cell lung cancer
20. Vinorelbine chemotherapy in non-small cell lung cancer: experience in elderly patients
21. Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients
22. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study
23. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer
24. Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small cell lung cancer (NSCLC)
25. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer
26. Randomised study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicentre trial including 612 patients
27. Long term analysis in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer
28. Economic evaluation of a randomised clinical trial comparing vinorelbine, vinorelbine plus cisplatin and vindesine plus cisplatin for non-small cell lung cancer
29. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer
30. Randomised trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a South West Oncology Group Study
31. Multicenter randomised clinical trial on high-dose epirubicin plus cis-platinum versus vinorelbine plus cis-platinum in advanced non small cell lung cancer
32. Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small cell lung cancer: a prospective randomised study of the Southern Italy Oncology Group (GOIM)
33. The emerging role of paclitaxel plus carboplatin in non-small cell lung cancer
34. A randomised phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): a South West Oncology Group (SWOG) trial
35. Silk purse in Atlanta: a commentary on SWOG-9509, an advanced non-small cell lung cancer trial
36. Carboplatin and vinorelbine in the treatment of advanced non-small cell lung cancer: a multicenter phase II study
37. Carboplatin and vinorelbine in advanced non-small cell lung cancer
38. Phase I study of vinorelbine and ifosfamide in advanced non-small cell lung cancer
39. Treatment of stage III-IV non small cell lung carcinoma with vinorelbine in combination with ifosfamide plus MESNA: a study by the Southern Italy Oncology Group (GOIM)
40. Vinorelbine and ifosfamide for unresectable non-small cell lung cancer
41. Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small cell lung carcinoma
42. First-line treatment of advanced non-small cell lung carcinoma with docetaxel and vinorelbine
43. A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer
44. Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small cell lung cancer
45. Activity and toxicity of gemcitabine and gemcitabine+vinorelbine in advanced non-small cell lung cancer in elderly patients. Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial
46. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimes
47. Cisplatin and ifosfamide with various doses of vinorelbine (Navelbine) in advanced non-small cell lung cancer
48. Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small cell lung cancer
49. Vinorelbine, ifosfamide and cisplatin in advanced non-small cell lung cancer
50. Cisplatin ifosfamide and vinorelbine combination chemotherapy in stage III-IV non-small cell lung cancer
51. Phase I/II study of vinorelbine, mitomycin and cisplatin for stage IIIB or IV non small cell lung cancer
52. Mitomycin C, vinorelbine, carboplatin plus granulocyte-macrophage colony-stimulating factor for treatment of advanced non-small cell lung carcinoma
53. Multicenter randomized trial comparin cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer
54. Combination chemotherapy with docetaxel, vinorelbine and cisplatin as first-line treatment of advanced non-small cell lung cancer: a multicentre phase II study of the Greek Cooperative Group for lung cancer
55. The multifractionated, twice-weekly dose schedule for a three-drug chemotherapy regimen. A phase I-II study of paclitaxel, cisplatin and vinorelbine
56. Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small cell lung cancer: a phase I study
57. Cisplatin, gemcitabine and vinorelbine combination therapy in advanced non-small cell lung cancer: a phase II randomised study of the Southern Italy Cooperative Oncology Group
58. Randomized trial comparing cisplatin, gemcitabine and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small cell lung cancer: interim analysis of a phase III trial of the Southern Italian Co-operative Oncology Group
59. A phase I-II study of pactlitaxel, ifosfamide and vinorelbine with Filgrastim (rhG-CSF) support in advanced non-small cell lung cancer
60. A phase I/II trial of neoadjuvant chemotherapy with cisplatin and vinorelbine followed by accelerated irradiation for patients with inoperable non-small cell lung carcinoma
61. Potentiation of radiation therapy by vinorelbine (Navelbine) in non-small cell lung cancer
62. Accelerated split-course (type B) thoracic radiation therapy plus vinorelbine/carboplatin combination chemotherapy in stage III inoperable non-small cell lung cancer
63. Phase I study of vinorelbine, cisplatin and concomitant thoracic radiation in the treatment of advanced chest malignancies
64. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy
65. Phase II trial of weekly iv vinorelbine in first-line advanced breast cancer chemotherapy
66. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma
67. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older
68. Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer
69. Combined doxorubicin/vinorelbine (Navelbine) therapy in the treatment of advanced breast cancer
70. A prospective, randomised phase III trial comparing chemotherapy with cyclophosphamide, doxorubin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast cancer
71. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8
72. Navelbine and fractionated dose doxorubicin improves first line treatment of advanced breast cancer. An overview of three phase II trials
73. Vinorelbine and epirubicin in metastatic breast cancer. A dose-finding study
74. Epirubicin/vinorelbine as first-line therapy in metastatic breast cancer
75. A dose-finding study for the combination of epidoxorubicin and vinorelbine, delivered every two weeks with G-CSF support in advanced breast cancer
76. Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer
77. A phase I/II study of vinorelbine, doxorubicin and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancer
78. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer
79. A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumours
80. First-line vinorelbine-mitoxantrone combination in metastatic breast cancer patients relapsing after an adjuvant anthracycline regimen: results of a phase II study
81. Is the combination FAC/FEC always the best regimen in advanced breast cancer? Utility of mitoxantrone and vinorelbine association as an alternative in some situations. Results from a phase III prospective randomized trial
82. Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method
83. Phase I-II study of vinorelbine in combination with 5-fluorouracil and Folinic acid as first-line chemotherapy in metastastic breast cancer: a regimen with a low subjective toxic burden
84. Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and L-leucovorin plus human granulocyte colony-stimulating factor
85. Five-day infusion fluorouracil plus vinorelbine iv in metastatic pre-treated breast cancer patients
86. Treatment with a non anthracycline regimen in advanced breast cancer
87. Phase II trial of a combination of vinorelbine, cyclophosphamide and 5-fluorouracil in the treatment of advanced breast cancer
88. Phase II study of vinorelbine and ifosfamide in anthracycline resistant metastatic breast cancer
89. Ifosfamide given by continuous intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: phase I-II clinical trial
90. Vinorelbine and mitomycin C in anthracycline-pretreated patients with advanced breast cancer
91. Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor
92. A phase II trial of vinorelbine and thiotepa in metastastic breast cancer
93. Combination cisplatin-vinorelbine for relapsed and chemotherapy-pretreated metastatic breast cancer
94. Phase I study of vinorelbine (Navelbine) and paclitaxel by simultaneous 3-h infusion with G-CSF support for untreated metastatic breast cancer
95. Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer
96. Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure
97. Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: a phase II study
98. Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: high complete response rate in a phase I-II study of doxorubicin treated patients
99. Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer
100. Docetaxel in combination with doxorubicin or vinorelbine
101. Docetaxel+vinorelbine with concurrent G-CSFT support: a phase II study in stage IV breast cancer
102. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor
103. Phase II study of estramustine, oral etoposide and vinorelbine in hormone-refractory prostate cancer
104. Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients
105. Results of a phase II trial of mitoxantrone and navelbine for hormone-refractory prostate cancer
106. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial
107. Vinorelbine in patients with recurrent multiple myelomas: a phase II study
108. An alternative treatment for relapsed/resistant multiple myeloma: vinorelbine plus high dose dexamethasone: two phase II studies
109. Oral idarubicin and vinorelbine for the treatment of advanced multiple myeloma: a pilot study
110. Phase II study of navelbine (NVB) in small cell lung cancer (SCLC)
111. A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, a South West Oncology Group study
112. Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive stage small-cell lung cancer: a phase II study
113. Phase II study of vinorelbine in patients with malignant pleural mesothelioma
114. Phase II trial of vinorelbine in metastatic squamous cell oesophageal carcinoma
115. Phase II Study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix
116. Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study
117. Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma
118. Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix
119. Phase II study of vinorelbine in patients with pre-treated advanced ovarian cancer: activity in platinum-resistant disease
120. Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer
121. A phase I study of a daily×3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer
122. Vinorelbine in pre-treated advanced head and neck squamous cell carcinoma. A phase II study
123. A phase II trial of vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
124. An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastastic squamous cell carcinoma of the head and neck
125. Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin and 5-fluorouracil: a multicenter phase II trial
126. Vinorelbine, cisplatin and 5-fluorouracil as initial treatment for previous untreated, unresectable squamous cell carcinoma of the head and neck
127. Vinorelbine, bleomycin and methotrexate as a salvage therapy for patients with head and neck squamous carcinoma in relapse after cisplatin/fluorouracil
128. Vinorelbine and carboplatin in recurrent and/or metastatic squamous cell carcinoma of the head and neck
129. Phase II study of vinorelbine (Navelbine) on previously treated Hodgkin's disease and non-Hodgkin's lymphomas
130. Vinorelbine in the treatment of lymphoma
131. Vinorelbine: an active drug for the management of patients with heavily pre-treated Hodgkin's disease
132. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease
133. Preclinical in vivo antitumour activity of vinflunine, a novel fluourinated vinca alkaloid